News Release Alliance combines Editas’ genome editing technology and expertise and Juno’s extensive CAR T and TCR platforms SEATTLE & CAMBRIDGE, Mass.–( BUSINESS WIRE )–Juno Therapeutics, Inc., a leading biopharmaceutical company focused on re-engaging the bod’s immune system to revolutionize the treatment of cancer, and Editas Medicine, a leader in genome editing, today announced an […]